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Abstract
Background: Next generation sequencing has yielded an unparalleled means of quickly determining the molecular
make-up of patient tumors. In conjunction with emerging, effective immunotherapeutics for a number of cancers, this
rapid data generation necessitates a paired high-throughput means of predicting and assessing neoantigens from
tumor variants that may stimulate immune response.
Results: Here we offer NeoPredPipe (Neoantigen Prediction Pipeline) as a contiguous means of predicting putative
neoantigens and their corresponding recognition potentials for both single and multi-region tumor samples.
NeoPredPipe is able to quickly provide summary information for researchers, and clinicians alike, on predicted
neoantigen burdens while providing high-level insights into tumor heterogeneity given somatic mutation calls and,
optionally, patient HLA haplotypes. Given an example dataset we show how NeoPredPipe is able to rapidly provide
insights into neoantigen heterogeneity, burden, and immune stimulation potential.
Conclusions: Through the integration of widely adopted tools for neoantigen discovery NeoPredPipe offers a
contiguous means of processing single and multi-region sequence data. NeoPredPipe is user-friendly and adaptable
for high-throughput performance. NeoPredPipe is freely available at https://github.com/MathOnco/NeoPredPipe.
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Background
Cancer cells are fraught with genomic variants in all
regions of the genome with high degrees of heterogeneity
in a spatially complex tumor. This intra-tumor hetero-
geneity (ITH) realizes a fitness landscape upon which
natural selection can act (reviewed by [1]). Neoanti-
gens, epitopes derived from proteins translated from
non-synonymous variants, are able to make their way to
the cell surface in the hopes of stimulating an immune
response after a number of cellular processing steps have
occurred, primarily proteosomal cleavage and binding
with major histocompatibility complexes (MHC) I or II.
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This binding depends upon the patient specific human
leukocyte antigen (HLA) alleles. From here, the bound
neoantigen with its MHC-Class I complex makes its way
to the cell surface where it may bind with cytotoxic T-
cell receptors thereby eliciting infiltration of cytotoxic
T-cells capable of detecting and eliminating cells carry-
ing the neoantigen in the absence of immune evading
tactics. The immune response is strongly influenced by
the total number of neoantigens within a tumor, espe-
cially in hyper-mutated cancers ([2]), as well as the ITH of
antigenic mutations ([3]). Recent advances in sequencing
techniques allow for multi-region sequencing approaches
whereby adjacent regions of the same tumor or tissue
are able to provide greater insights into variant clon-
ality (i.e. truly clonal, subclonal, or shared). There is
increasing evidence that the neoantigen landscape of
tumours can be highly heterogeneous, containing regions
of subclonal immune escape and significantly different
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neoantigen load that can influence a patient’s response to
immunotherapy [4–6].
A number of tools are available that provide mutated
peptide annotation, binding affinity prediction, wild-type
and mutant peptide comparison, and neoantigen ranking
based on these measures [7–10]. Their input varies from
raw sequencing files (e.g. fastq) [7, 8, 10] to highly anno-
tated vcf files [9]; some provide HLA-typing as part of
their pipeline [7, 10], but require further dependencies for
HLAtyping software. Most rely on a version of netMHC
or netMHCpan for binding prediction, but [9] offers a
choice of additional software. For an in-depth comparison
of available pipelines for neoantigen calling, we refer the
reader to the recent review of Lancaster et al. [11].
Despite the increasing number and diversity of
neoantigen-prediction tools, none of them possess the
capability of providing predicitions on multi-region
sequence data and assessing ITH of the antigenic land-
scape of tumours. Here, we present NeoPredPipe, a
pipeline connecting commonly used bioinformatic
software via custom python scripts to allow for the
processing of single and multi-region variant call format
(VCF) files, variant annotations, neoantigen predictions,
cross-referencing with known epitopes, and performing
in silico TCR recognition potential predictions in a single,
clear, and proficient workflow (Fig. 1).
Implementation
The first stage in neoantigen identification from a VCF
file is the proper annotation of variants to identify non-
synonymous variants. To this end, NeoPredPipe employs
the widely used and efficient genomics tool, ANNOVAR
([12]). Specifically, ANNOVAR processes samples in a
way that prioritizes exonic variants, this step provides
a useful means for quickly partitioning variant calls for
downstream applications. The user is able to specify the
genome build that they would like to use, provided it
is compatible with ANNOVAR. Finally, using the cod-
ing_change function of ANNOVAR and custom code, the
mutated amino acid sequence is predicted from annotated
nonsynonymous variant calls, and the peptide sequence
surrounding the newly introduced amino acid is extracted
for epitope prediction. From this step, mutations that give
rise to a single amino acid change, and mutations that
mutate a larger peptide segment (e.g. indels and stop-
losses) are handled separately and reported in separate
files to help further assessment.
Once the VCF files have been annotated and parti-
tioned with ANNOVAR, the program determines if HLA
haplotypes have been provided by the user containing
the HLA-A, -B, and -C haplotypes. NeoPredPipe does
not include HLA allele identification as this step in the
pipeline is highly dependent upon the source of the data
(WES, WGS, targeted gene panels, transcriptome data, or
Fig. 1 NeoPredPipe workflow differentiating between user steps
(green) and execution processes (purple). NeoPredPipe provides low
level details and high level summary statistics as output for
downstream analysis (red)
conducted via experimental methods), but the pipeline’s
github page provides detailed advice on haplotyping from
WES/WGS data using the popular tool POLYSOLVER
[13], and the output of POLYSOLVER is automatically
processed in NeoPredPipe. In cases where no HLA hap-
lotype information is available the most common alleles
of each haplotype are assessed; while in cases where
the HLA haplotypes are homozygous only that HLA
haplotype is used for prediction. HLA haplotypes are
cross-referenced with available HLA haplotypes prior to
executing netMHCpan ([14]) for the primary neoanti-
gen predictions. As with the primary tool, the user is
able to specify the epitope lengths to conduct predic-
tions for (typically epitopes of 8-, 9-, or 10-mers). The
output from this process yields a single file containing
either filtered or unfiltered (dependent on user options)
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neoantigen predictions with information on the sample
possessing the neoantigen and, in the case of multi-region
variant calling, a presence/absence indicator for each of
the sequenced regions. These predicted neoantigens are
then, optionally, cross-referenced with normal peptides
utilizing PeptideMatch ([15]), whereby the candidate epi-
topes are assessed for novelty against a reference pro-
teome that can be supplied by the user as a fasta file
(e.g. from Ensembl or UniProt). When available, users
may also provide expression data as a tsv file specific to
each sample (or a single reference file) to quickly assess
expression levels of the gene carrying a predicted neoanti-
gen. This information is included in the final output
table.
The steps outlined above deliver candidate informa-
tion for neoantigens from provided variant calls that may
be presented to cytotoxic T-cells, however, this does not
inform the likelihood of a neoantigen eliciting an immune
response (i.e. being recognised by a TCR). In order to pre-
dict the recognition potential we employ the algorithms
and process utilized by [16]. The recognition potential
is defined as the product of A and R, where A is the
amplitude of the ratio of the relative probabilities of bind-
ing for the wild-type and mutant epitopes to the MHC-
class I molecules; and R is a measure of similarity to
pathogenic peptides, meant to represent the probability
that the neoantigen in question is recognised by a TCR
clone already present in the tissue/blood. To define A it is
necessary to perform neoantigen predictions for the wild-
type and mutant epitope: this is not performed by default
by NeoPredPipe, but is supplied as an option to employ
as a contiguous pipeline. To define R, NeoPredPipe uti-
lizes the multistate thermodynamic model employed by
[16], which requires alignment scores for each epitope to a
curated Immune Epitope Database list of known epitopes
(can be refined and updated by the user, but is provided).
In order to incorporate the ability to assess ITH in
regards to both effective mutations (non-synonymous
variants and indels) and neoantigen burdens, NeoPred-
Pipe is capable of handling multi-region VCF files; further
these files can be multi-region in only a select number
of samples and differ in the number of regions. Simi-
larly, NeoPredPipe can process multi-region expression
data for samples where information on regions are com-
piled into separate columns. Thus NeoPredPipe is able to
efficiently handle various, potentially multi-region experi-
mental designs for neoantigen prediction and assessments
providing a summary table and an optional web-based
visualization tool for downstream statistical and in-depth
analysis.
Results
The output of the pipeline depends largely on the options
set by the user, but at the very least, NeoPredPipe provides
two tables of putative neoantigens and their predicted
binding affinities, one for single nucleotide/amino acid,
and one for indel(-type) variants. With additional options
selected it is possible to include, within a single out-
put, whether an epitope matches a reference proteome,
its expression on the RNA level and the neoantigen’s
recognition potential. In additon, for rapid assessment,
NeoPredPipe yields summary statistics on the neoanti-
gen burden for each sample, a rapidly executed web-
based visualization, as well as information to assess ITH
by reporting neoantigen burdens for clonal, subclonal,
and shared variants for multi-region samples. A detailed
description of NeoPredPipe’s output tables and each field
in these can be found at https://github.com/MathOnco/
NeoPredPipe.
Use Case
While a small, two sample, multi-region example dataset
is provided with the source code for users, we demon-
strate the usefulness of NeoPredPipe by applying it to a
previously published dataset examining the evolutionary
landscape of colorectal tumors [17]. We select two exem-
plary patient samples (Adenoma 3 and Carcinoma 7 in the
original paper) from the dataset, and apply our pipeline
using default parameters to evaluate neoantigens in each
sample. Figure 2 illustrates the information included in
the standard output of NeoPredPipe and potential analysis
that can be performed if NeoPredPipe is combined with
the output of other standard bioinformatic methods.
Figure 2a provides a summary of the complex interac-
tions between different regions of Adenoma 3, and high-
lights both Region 4, which harbours the highest amount
of subclonal (only present in a single region) neoanti-
gens, and the overall clonality of the sample, with 72
neoantigens detected in all regions. For quick analysis,
NeoPredPipe directly outputs a summary of the clonal-
ity of neoantigens, also divided into categories of strong
and weak binders (peptides with a netMHCpan percentile
rank ≤ 0.5 and ≤ 2, respectively, as recommended in
[14]). Figure 2b visualizes this summary on two bar-charts
for Adenoma 3 and Carcinoma 7. We find that whilst
the number of shared neoantigens (present in more than
one, but not all regions) is highly similar between the
two samples, Carcinoma 7 harbours both more clonal
(present in all regions) and subclonal neoantigens; and
in total 26% of the neoantigens are clonal, compared
to 16% of Adenoma 3. Figure 2c shows the recognition
potential value for all neoantigens in the two samples.
NeoPredPipe identified 10 peptides in Adenoma 3 and 9
in Carcinoma 7 with a recognition potential value above
1. In Fig. 2d, we provide an example of integrating Neo-
PredPipe outputs with downstream multi-region variant
analysis. By inferring phylogenetic trees of each tumor,
constructed using all exonic mutations with a variant
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allele frequency above 0.05 (see [17] for full methods),
we find that neoantigen distributions across regions can
reflect the phylogenetic distance of regions and clonal
structure of samples. 31% and 23.5% of total exonic muta-
tions are clonal in Carcinoma 7 and Adenoma 3, similarly
to the clonality of neoantigens shown in Panel B. This
approach also highlights regions with neoantigen loads
different from their closest neighbors, such as Region61
and Region62 of Carcinoma 7. Therefore the analysis can
inform future experimental and bioinformatic investiga-
tions of samples allowing for new evolutionary and mech-
anistic insights into tumor development, evolution, and
progression.
Conclusions
We present NeoPredPipe, an efficient, high-throughput,
and user-friendly pipeline for neoantigen prediction and
interrogation for single and multi-region tumor VCF
files. By tying together commonly utilized bioinformat-
ics toolsets and integrating recent advances in neoantigen
assessment, NeoPredPipe yields concise information typ-
ically required by researchers and clinicians. Through
user options, based on the individuals own computational
limitations, the pipeline is scalable for a high performance
computing (HPC) cluster environment and customizable
for individual research questions. Furthermore, unlike
existing methods[7–10], NeoPredPipe can process a
directory containing numerous samples in a single com-
mand; therefore provides a user-friendly way for not
computer-proficient users to analyse the output of large
studies or compare against reference datasets. All source
code and an extensive read me for each component of




Project home page: https://github.com/MathOnco/
NeoPredPipe
Operating system: Unix-based operating system
Programming languages: Python and Bash
Other requirements: Python 2.7, ANNOVAR,
netMHCpan, PeptideMatch, and (optionally) NCBI
BlastX+.
License: GNU GPLv3




Fig. 2 Analysis of neoantigens in two colorectal tumors using NeoPredPipe. a Venn diagram of all neoantigens in the five regions of Adenoma 3. b
Number of neoantigens in the two samples that are clonal (present in all regions, shown in blue), shared (present in at least two regions, in yellow) or
subclonal (present in a single region, red). Separate counts of weak and strong MHC-binding neoantigens (WB and SB, respectively) are also shown. c
Distribution of recognition potential values of neoantigens present in Adenoma 3 (green) and Carcinoma 7 (red). The boxplots represent the median
and upper and lower 25 percentile. Only neoantigens with recognition potential higher than zero are shown. d Phylogenetic tree reconstructed from
all exonic mutations for Adenoma 3 (left) and Carcinoma 7 (right). Pie-charts and the bar-charts represent the number of weak (orange) and strong
(red) binder neoantigens assigned to each branch. The size of each circle is proportional to the percentage of total neoantigens on that branch
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